

IN THE SPECIFICATIONS:

Please add the following sentence to the first line of the Specification:

*B<sup>1</sup>*  
This is a 371 of International Application No. PCT/GB98/02317, filed July 31, 1998, which  
claims priority from International Application No. PCT/PCT/GB97/16224, filed July 31, 1997.

IN THE CLAIMS:

Please cancel claims 54-56, 58, 61-62 and 71.

Please amend claims 53, 57, 65 and 68 as follows:

*B<sup>2</sup>*  
53. A method of inhibiting mutagenesis in an organism, which method comprises  
administering to the organism, an effective anti-mutagenic amount of an extract from Aristolochia  
taliscana, said extract having been prepared by a process which includes extracting plant material  
from Aristolochia taliscana with an organic solvent, such that the extract is substantially free of  
aristolochic acids.

*B<sup>3</sup>*  
57. A method of inhibiting fungal growth in a substrate, which method comprises  
administering to the substrate an effective anti-fungal amount of an extract from Aristolochia  
taliscana, said extract having been prepared by a process which includes extracting plant material  
from Aristolochia taliscana with an organic solvent, such that the extract is substantially free of  
aristolochic acids.

*Sub C3* 65. A composition comprising an extract from Aristolochia taliscana, wherein the extract has been prepared by extraction of plant material from the Aristolochia species with an organic solvent and contains at least 10% by weight of a eupomatenoid, wherein the extract is substantially free of aristolochic acids.

*Sub C4* 68. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an extract from Aristolochia taliscana wherein the extract has been prepared by extraction of plant material from the Aristolochia species with an organic solvent, wherein the extract contains at least 25% by weight of a phenolic eupomatenoid compound, at least 8% of Licarin-A and at least 8% by weight of a non-phenolic eupomatenoid compound, and wherein the extract is substantially free of aristolochic acids.

**REMARKS**

This Amendment is filed in response to the Office Action dated January 4, 2001. A continued prosecution application was filed on July 3, 2001. The Examiner has rejected claims 53-64 under 35 U.S.C. §112, first paragraph, stating that the specification "does not reasonably provide enablement for a method of inhibiting mutagenesis, inhibiting fungal growth or inhibiting